Indapamide is used for: Hypertension; Congestive heart failure.
Recorded in the NepalDoc medicine catalog for Indapamide.
Indapamide tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs. Indapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failure.
From the U.S. FDA-approved label for Indapamide. Full label: DailyMed.
Indapamide tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs. Indapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failure. Usage in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard (see PRECAUTIONS below). Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Indapamide is indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (however, see PRECAUTIONS below).
From the U.S. FDA-approved label for Indapamide. Full label: DailyMed.
DOSAGE & ADMINISTRATION Hypertension: The adult starting indapamide dose for hypertension is 1.25 mg as a single daily dose taken in the morning. If the response to 1.25 mg is not satisfactory after 4 weeks, the daily dose may be increased to 2.5 mg taken once daily. If the response to 2.5 mg is not satisfactory after 4 weeks, the daily dose may be increased to 5.0 mg taken once daily, but adding another antihypertensive should be considered.
Directions from the U.S. FDA-approved label for Indapamide — your doctor or pharmacist may advise differently.
Known hypersensitivity to indapamide or to other sulfonamide-derived drugs.
Excerpt from the U.S. FDA-approved label for Indapamide. Talk to a pharmacist or doctor before use.
Severe cases of hyponatremia, accompanied by hypokalemia have been reported with recommended doses of indapamide. This occurred primarily in elderly females. (See PRECAUTIONS, Geriatric Use.) This appears to be dose related. Also, a large case-controlled pharmacoepidemiology study indicates that there is an increased risk of hyponatremia with indapamide 2.5 mg and 5 mg doses. Hyponatremia considered possibly clinically significant (< 125 mEq/L) has not been observed in clinical trials with the 1.25 mg dosage (see PRECAUTIONS ).
Warnings and precautions excerpt from the U.S. FDA-approved label for Indapamide — not a complete list. Talk to a pharmacist or doctor before use.
Most adverse effects have been mild and transient. The clinical adverse reactions listed in Table 1 represent data from Phase II/III placebo-controlled studies (306 patients given indapamide 1.25 mg). The clinical adverse reactions listed in Table 2 represent data from Phase II placebo-controlled studies and long-term controlled clinical trials (426patients given indapamide 2.5 mg or 5.0 mg).
Excerpt from the U.S. FDA-approved label for Indapamide — not a complete list. Talk to a pharmacist or doctor about side effects.
5 brands · 3 makers in the NepalDoc catalog — see the full Indapamide guide →
Store at 20° to 25°C (68° to 77°F).
Storage information from the U.S. FDA-approved label for Indapamide.
What is Indapa?
Indapa 2.5mg Tablet is a Indapamide medicine made by M.J. BIOPHARM PL LTD. It comes as 2.5mg Tablet.
What is Indapa used for?
Indapamide is used for Hypertension, Congestive heart failure.
What is the generic name of Indapa?
The generic name of Indapa is Indapamide.
Which brands of Indapamide are available in Nepal?
5 brands of Indapamide are listed in the NepalDoc catalog, from 3 makers — including Indapa SR 1.5mg Tablet, Indicontin 1.5 Tablet, Lorvas 2.5mg Tablet, Lorvas SR 1.5mg Tablet.
What are the side effects of Indapamide?
Most adverse effects have been mild and transient. The clinical adverse reactions listed in Table 1 represent data from Phase II/III placebo-controlled studies (306 patients given indapamide 1.25 mg).
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
